Multiple Assemblies exist for SMTL entry 5v24
Structure-based drug design of novel ASK1 inhibitors using a fully integrated lead optimization strategy; X-RAY DIFFRACTION 2.50 Å

	SMTL ID 5v24.1 Ligands 2-[4-(propan-2-yl)-4H-1,2,4-triazol-3-yl]-N-(pyridin-2-yl)-1,3-thiazole-4-carboxamide Polypeptides Mitogen-activated protein kinase kinase kinase 5 Oligo-state monomer
	SMTL ID 5v24.2 Ligands 2-[4-(propan-2-yl)-4H-1,2,4-triazol-3-yl]-N-(pyridin-2-yl)-1,3-thiazole-4-carboxamide Polypeptides Mitogen-activated protein kinase kinase kinase 5 Oligo-state monomer